Moreover, Sugiyama et al found that targeting EGFR in combination with anti-PD-1 mAb could increase the efficacy of lung cancer immunotherapy.[39] EGFR-mAb as a single treatment of EGFR-activated mutant NSCLC or in combination with PD-1/PD-L1 inhibitors may be feasible for patients with EGFR-TKIs-resistant non-small cell lung cancer. Here, CD274 is linked to non-small cell lung carcinoma.